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a b s t r a c t
Objectives: To evaluate the prevalence of subclinical atherosclerosis in patients with anky-
losing spondylitis (AS) in comparison to controls with similar cardiovascular risk factors. 
Methods: Forty-two consecutive patients with AS and 42 controls matched for age (43.3 ± 
11.7 vs. 43.7 ± 11.3, P = 0.89), gender, smoking, diabetes mellitus and arterial hypertension 
were enrolled. Participants were excluded if a personal cardiovascular disease (CV) history 
was present. A questionnaire recording demographic data, medical and medication history 
was fulfi lled.  Blood pressure, abdominal circumference, height and weight were measured. 
Lipid profi le was determined in a 12-hour fastened blood sample. Ultrasound analysis of 
the common carotid artery was performed by one blind observer. The distance between the 
lumen-intima interface and the leading edge of the media-adventitia interface (IMT) was 
measured and participants were also evaluated for the presence of plaques.
Results: The comparative analysis of demographic and cardiovascular risk factors between 
AS patients and controls did not reveal statistically signifi cant differences. Also, no signifi -
cant differences between groups were observed for TC, HDL-C, T-C/HDL-C, LDL-C, triglycer-
ides, or dyslipidemia frequency. IMT measures were not different in AS and controls (0.62 ± 
0.09 vs. 0.61 ± 0.09, P = 0.39) as well as plaques frequencies (19% vs. 17%, P = 0.78).
Conclusions: Subclinical atherosclerosis assessed through carotid ultrasound imaging was 
not more prevalent in the AS group when compared to controls with similar cardiovascular 
risks. Our observations may imply that CV risk factors may have more infl uence on the CV 
system than AS itself. These fi ndings should be confi rmed in a larger population with a 
prospective study design. 
© 2013 Elsevier Editora Ltda. All rights reserved.
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Aterosclerose subclínica em pacientes com espondilite anquilosante: 
há um papel para a infl amação?
Palavras-chave:
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Risco cardiovascular
r e s u m o
Objetivos: Avaliar a prevalência de aterosclerose subclínica em pacientes com espondilite 
anquilosante (EA) em comparação com controles com fatores de risco cardiovasculares 
similares.
Métodos: Foram recrutados 42 pacientes consecutivos com EA e 42 controles equiparados 
para idade (43,3 ± 11,7 vs. 43,7 ± 11,3, P = 0,89), gênero, tabagismo, diabetes mellitus e hi-
pertensão arterial. Qualquer participante seria excluído se estivesse presente uma história 
pessoal de doença cardiovascular (CV). Foi preenchido um questionário registrando dados 
demográfi cos e histórias médica e de medicação. Foram determinados: pressão arterial, 
circunferência abdominal, altura e peso. O perfi l lipídico foi determinado em uma amostra 
de sangue com 12 horas em jejum. Foi realizada uma análise ultrassonográfi ca da artéria 
carótida comum por um observador desconhecedor da pesquisa. Foi medida a distância 
entre a interface lúmen-íntima e a borda de ataque da interface média-adventícia (EIM) e 
os participantes também foram avaliados para presença de placas.
Resultados: A análise comparativa dos fatores de risco demográfi cos e cardiovasculares en-
tre pacientes com EA e controles não revelou diferenças estatisticamente signifi cativas. 
Também não foram observadas diferenças signifi cativas entre grupos para TC, HDL-C, T-C/
HDL-C, LDL-C, triglicerídeos ou frequência de dislipidemia. As medidas de EIM não foram 
diferentes em EA e controles (0,62 ± 0,09 vs. 0,61 ± 0,09, P = 0,39) e nem as frequências de 
placas (19% vs. 17%, P = 0,78).
Conclusões: A aterosclerose subclínica avaliada por meio de imagens ultrassonográfi cas da 
carótida não foi mais prevalente no grupo EA, em comparação com os controles com riscos 
cardiovasculares similares. Nossas observações podem implicar que os fatores de risco CV 
podem ter mais infl uência no sistema CV versus a própria EA. Esses achados devem ser 
confi rmados em uma população maior, por meio de um estudo prospectivo. 
© 2013 Elsevier Editora Ltda. Todos os direitos reservados.
Introduction
Ankylosing spondylitis (AS) is a chronic, infl ammatory rheu-
matic disease. Its musculoskeletal manifestations include 
both infl ammation and structural damage. Characteristic 
extra-articular manifestations include aortitis, cardiac con-
duction defects, pulmonary fi brosis and infl ammatory bowel 
disease indicating that AS is a systemic disease.
AS is known primarily for causing a lifetime of pain, im-
paired physical function, work disability, and decreased 
quality of life, rather than for shortening life itself. However, 
patients with AS also experience premature mortality.1 The 
standardized mortality rates (SMR) associated with AS are ap-
proximately 50% higher than in the general population.2,3 The 
four non-inception cohort studies published to date quote 
SMRs of 1.33,4,5 1.56 and 1.8.7 
Increased mortality is largely attributable to cardiovascu-
lar diseases (CV).3 A recent large population based study has 
shown more ischemic heart disease (prevalence ratio 1.2), pe-
ripheral vascular disease (ratio 1.6), atherosclerosis (ratio 1.5), 
congestive heart failure (1.8) and more cardiovascular risk 
factors (prevalence ratios between 1.3 and 1.7) in AS patients 
compared to healthy controls.8
It is unclear whether the increased cardiovascular risk of 
AS patients could be explained by traditional cardiovascular 
risk factors alone. In fact, there is increasing evidence that 
the underlying infl ammatory process in chronic infl ammato-
ry conditions resembles the chronic infl ammatory processes 
that contribute to various stages of atherothrombosis, from 
early atheroma formation to plaque instability and thrombus 
formation.9 However, it is unknown whether AS patients with-
out CV disease risk factors show early signs of large artery 
damage compared to controls, and if so, what the determi-
nants of such large-vessel abnormalities are. This knowledge 
could prove useful for development of risk stratifi cation, in-
tervention strategies and for a better disease understanding.
High-resolution ultrasonography can be used to measure 
the intima-media thickness (IMT) as well as vascular elas-
ticity of the carotid artery. An increased carotid IMT refl ects 
the atherosclerotic burden and predicts the development of 
(clinically apparent) CV disease in the general population.10,11 
Hence, this study was designed to determine whether signs 
of subclinical atherosclerosis are more prominent in a sample 
of AS patients compared to controls without the disease but 
with similar cardiovascular risks. Other studies assessing IMT 
in AS patients and controls have been published but results 
were contradictory12-18 and will be discussed further.
Methods
Study population: forty-two consecutive patients with AS at-
tending the outpatient clinic of the University Hospital of the 
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Federal University of Santa Catarina, Brazil. All patients ful-
fi lled the modifi ed New York diagnostic criteria for AS.19 Forty-
two volunteers (hospital staff or patients who attended the 
General Clinic for the University employees) matched for age, 
sex, smoking (current or in the last fi ve years), diabetes melli-
tus and systemic arterial hypertension served as controls. All 
participants gave written informed consent and the institu-
tional ethics committees of the University Hospital approved 
the study protocol.
Patients and controls were excluded if a personal CV dis-
ease history was present (myocardial infarction, percutane-
ous transluminal coronary angioplasty, surgery for ischemic 
heart disease, stroke, transient ischemic attack, carotid end-
arterectomy, peripheral arterial reconstructive surgery, or 
limb amputation). 
Patients and controls were examined by a research phy-
sician. A questionnaire recording demographic data, medical 
and medication history was fulfi lled. Blood pressure, abdomi-
nal circumference, height and weight were measured. Body 
mass index (BMI) was calculated as the ratio of weight and 
height squared. We considered the patient/control as diabetic 
if they referred hypoglycemic drug use or in the presence of 
least two glycemic tests higher than 126 mg/dL. We consid-
ered the patient/control as hypertensive if they referred an-
ti-hypertensive drugs use or a systolic blood pressure > 140 
mmHg or diastolic blood pressure > 90 mmHg measured in 
two different occasions. We considered the patient/control as 
dyslipidemic if they referred hypolipemiants drugs use or if 
they presented at least one of the following: LDL-C (low den-
sity lipoprotein) > 130 mg/dL; triglycerides > 150 mg/dL; HDL-
C (high-density lipoprotein) < 40 mg/dL.
Laboratory variables were determined in a 12-hour fas-
tened blood sample and included: TC (total cholesterol), 
HDL-C, LDL-C, triglycerides (all analyzed by enzymatic tech-
niques); C-reactive protein (CRP by nephelometry method), 
and erythrocyte sedimentation rate (ESR by Westergreen 
method).
Arterial measurements were conducted in a quiet room 
after 15 minutes of rest, with the subjects in supine position. 
Ultrasound analysis of the common carotid artery (bilater-
al) was performed by a cardiologist who were unaware of 
the participants’ clinical or laboratory characteristics. Mea-
surements were performed using a B mode high resolution 
ultrasound ATL HDI 3000 (Phillips Bothel, WA, USA) with a 
5-12MHz linear probe. The distance between the lumen-in-
tima interface and the leading edge of the media-adventitia 
interface of the far wall corresponds with IMT. After localiza-
tion of the common carotid artery, cross-sectional measure-
ments were performed 10 mm proximal from the carotid 
bulb. Sites with mural atherosclerotic plaque were excluded 
while measuring. Three measurements were performed at 
each side. A mean of each side (right or left) was calculated 
and fi nally the mean of both sides (mean) was achieved. We 
defi ned plaques as focal widening of the vessel wall of 50% 
relative to adjacent segments with protrusion into the lu-
men or a IMT > 1.5 mm.
The distribution of each continuous variable was exam-
ined graphically and statistically for normality. Numerical 
data are summarized as the mean and standard deviation 
(SD). Variables not normally distributed were compared us-
ing the Wilcoxon nonparametric test for differences. Vari-
ables normally distributed were compared using students’ 
tests. Categorical data among groups were compared by the 
chi-square or the Fischer exact test statistics when appropri-
ate. Some results were evaluated according to the established 
normal values and were subsequently ranked as elevated or 
depressed. A statistical signifi cance was set at P < 0.05. All sta-
tistical analyses were performed using NCSS software.
Results
Comparative analysis of demographic and cardiovascular risk 
factors between AS patients and controls did not reveal sta-
tistically signifi cant differences as demonstrated in table 1. 
AS mean age was 43.3 ± 11.7 years-old and the mean time of 
disease duration was 15.9 years.
Also, no signifi cant differences between groups were ob-
served for TC, HDL-C, T-C/HDL-C, LDL-C, triglycerides, or dys-
lipidemia frequency as showed in table 2. AS patients had a 
signifi cant elevation in CRP (38.1% vs. 14.3%, P = 0.01), but not 
in the ESR.
In table 3 we demonstrate medications use in both groups. 
31% against 11.9% of AS patients were on hypolipemiants (P = 
0.03). Anti-TNF was used in 66.6% of all AS patients. 
There was no difference in IMT measures in AS and con-
trols (0.62 ± 0.09 vs. 0.61 ± 0.09, P = 0.39). Also no difference 
was observed in the frequency of plaques (table 4).
Table 1 – Clinical and demographic features in AS and 
controls.
AS (n = 42) Controls (n = 42) P
Age (years) ± SD 43.3 ± 11.7 43.7 ± 11.3 0.89 
Male, n (%) 26 (61.9) 26 (61.9) 1.0 
Caucasian, n (%) 35 (83.3) 40 (95.2) 0.08 
Smokers, n (%) 8 (19.04) 8 (19.04) 1.0 
CV FH, n (%) 14 (33.3) 12 (28.57) 0.64 
AH, n (%) 15 (35.7) 11 (26.2) 0.35 
DM, n (%) 3 (7.1) 3 (7.1) 1.0 
BMI (kg/m2) ± SD 26.5 ± 3.9 27.6 ± 4.5 0.25 
AC (cm) ± SD 90.1 ± 12.3 91.6 ± 12.8 0.58 
AS, ankylosing spondylitis; SD, standard deviation; CV FH, 
cardiovascular family history; AH, arterial hypertension; DM, diabetes 
mellitus; BMI, body mass index; AC, abdominal circumference.
Table 2 – Laboratory profi le in AS and controls.
AS 
(n = 42)
Controls 
(n = 42)
P
Total-cholesterol (mg/dL) ± SD 194.8 ± 36.0 196.8±36.4 0.81 
HDL-C (mg/dl) ± SD 52.7 ± 10.9 52.1±14.9 0.82 
LDL-C (mg/dl) ± SD 120.1 ± 32.4 119.3 ± 35.1 0.92 
Tryglicerides (mg/dL) ± SD 109.7 ± 49.9 126.8 ± 103.7 0.88 
CT/HDL ± SD 3.8 ± 0.9 4.0 ± 1.3 0.36 
Dyslipidemia, n (%) 25 (59.5) 26 (62) 0.82 
Elevated CRP, n (%) 16 (38.1) 6 (14.3) 0.01
ESR (mm/1st hour) ±  SD 22.2 ± 17.7 20.3 ± 16.8 0.29
AS, ankylosing spondylitis; SD, standard deviation, CRP, C-reactive 
protein; ESR, erythrocyte sedimentation rate.
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Discussion
Given that infl ammation has increasingly been acknowledged 
as the reason rheumatic patients bear elevated CV risk,20 we 
selected a study population of AS patients matched for fi ve 
major CV risk factors in order to better assign for this issue. 
Our study revealed that CV risk among AS patients as in-
dicated by IMT is not different from controls without the dis-
ease. On the opposite, Peters at al found a greater IMT in AS 
patients in comparison with controls.12 However, the authors 
also found a high CV risk factor profi le in patients with AS, 
and some of these risk factors (lipids and BMI) were associated 
with a greater carotid IMT and increased arterial stiffness. No 
association between large-vessel properties and higher Bath 
AS indices or CRP values were found. Also, Mathieu et al.14 
found signifi cantly increased IMT in the AS group compared 
with healthy controls. However, after adjustment for con-
founding factors, only an underlying trend towards increased 
IMT was present. IMT was positively correlated with tobacco 
use and blood pressure but not correlated with CRP level or 
mSASS. In the AS group, IMT was correlated with traditional 
risk factors, such as smoking and systolic blood pressure.
Although the cross-sectional study design does not permit a 
good estimate of the cumulative infl ammatory burden and the 
small series of patients are associated with a low statistical pow-
er, their results suggest that an adverse CV risk profi le may cause, 
at least partly, the greater IMT found by them and there is no 
suffi cient evidence to support a role of biological infl ammation.
Gonzalez et al., recruited 64 AS patients and 64 matched 
controls with no cardiovascular morbid. Patients with AS ex-
hibited greater carotid IMT than did matched controls (mean 
± SD, 0.74 ± 0.21 mm vs. 0.67 ± 0.14 mm; P = 0.01; differences 
of means, 0.077; 95% confi dence interval [CI], 0.016-0.139). In 
this case, although the best predictors for carotid plaques in 
patients with AS were erythrocyte sedimentation rate (ESR) at 
time of disease diagnosis (odds ratio [OR], 1.18; 95% CI, 1.04-
1.33; P = 0.01) and duration of disease (OR, 1.39; 95% CI, 1.01-
1.92; p = 0.05); there was no signifi cant correlation between 
carotid IMT and either ESR or C-reactive protein.13
Indeed, many of the traditional risk factors for cardio-
vascular disease are present in the AS versus the general 
population, including a higher incidence of hypertension, 
elevated lipids, increased fi brinogen and CRP levels, and 
poorer physical activity levels. BMI and total cholesterol and 
triglycerides have been positively correlated with IMT and/
or arterial stiffness.21
In accordance with our fi ndings, Choe et al. found that ca-
rotid IMT and parameters related with arterial elastic proper-
ties in young AS patients without clinically evident cardiovas-
cular risk factors were not different from those of sex- and 
age-matched healthy controls. Serum levels of TNF-a, IL-6, 
and MCP-1 did not refl ect the degree of carotid subclinical 
atherosclerosis.15 In addition,  recently, Capkin et al. evaluated 
a total of 67 AS patients, and age, sex, body mass index (BMI) 
smoking status, lipid profi les and blood pressure-matched 
healthy control subjects (n = 34). They also found no differ-
ence in IMT-C between groups. 
Our study has some limitations. No disease activity index 
was analyzed. However, the isolated disease activity mea-
sure would not allow drawing any conclusions about the in-
fl ammatory burden possibly associated with atherosclerosis. 
Also, 66.6% of patients were on anti-TNF treatment. A sub-
analysis comparing AS patients suggested that the group on 
anti-TNF treatment (n = 28) was not different from the group 
treated with non-biologic drugs (n = 14) when it comes to 
the IMT, however, they had numerically less plaques (10.7% 
vs. 35.7%, P = 0.09). Although this study was not designed 
to assign for this exact issue, our fi nding raises the ques-
tion about the anti-TNF playing a part to a better cardiovas-
cular outcome. Studies on ischemic heart disease related 
mortality and morbidity following anti-TNF therapy have 
shown mixed results. Ferrante et al.22 observed a signifi cant 
decrease of carotid IMT in anti-TNF-treated RA patients af-
ter two years but not in the group treated with methotrex-
ate alone, although signifi cant improvements were seen in 
measures of disease activity, CRP and fi brinogen levels with 
both type of treatments. It is thought though that anti-TNF 
treatment has the potential not only to reduce infl amma-
tion but also to modify traditional cardiovascular risk factors 
and endothelial dysfunction in RA.23,24 Additionally, one third 
of the AS patients were more frequently on hypolipemiants 
(31% vs. 11,9%), although dyslipidemia (as defi ned by this 
study) was not more prevalent in AS patients. However, it 
well known that statins’s vascular improvement is indepen-
dent of statins’ cholesterol-lowering actions, fact that has 
been associated with their anti-infl ammatory and immu-
nomodulatory properties.25 Similarly to the anti-TNF treat-
ment, because of the study design we cannot be conclusive 
about statins contribution for a possible better cardiovascu-
lar outcome on these AS cases.
In conclusion, our observations are in agreement with the 
fi ndings of others and may imply that CV risk factors have 
more infl uence on the CV system than AS itself. However, we 
could not be conclusive because of the anti-TNF and hypoli-
pemiants use. These fi ndings should be confi rmed in a larger 
population with a prospective study design. Further research 
concerning the pathogenesis of increased cardiovascular risk 
in AS patients should be high priority, as many risk factors are 
likely to be modifi able.
Table 3 – Medications use in AS and controls.
AS (n = 42) Controls (n = 42) P
Glucocorticoid, n (%) 8 (19)
NSAID, n (%) 22 (52.3) 
Sulfasalazine, n (%) 6 (14.3) 
Methotrexate, n (%) 5 (11.9) 
Anti-TNF, n (%) 28 (66.6) 
Hypolipemianta, n (%) 13 (31.0) 5 (11.9) 0.03
AS, ankylosing spondylitis; NSAID, non-steroidal anti-infl ammatory 
drugs.
aAll hypolipemiants used were from the statins group
Table 4 – Carotid ultrasound in AS and controls.
AS (n = 42) Controls (n = 42) P
IMT (mm) ± SD 0.62 ± 0.09  0.61 ± 0.09 0.39 
Plaques, n (%) 8 (19.0) 7 (17.0) 0.78 
AS, ankylosing spondylitis; SD, standard deviation.
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